Though cumulative safety data for next-generation BTKis have been positive1,54, clinicians’ safety concerns for pharmacologic BTK inhibitors may still be overshadowed by knowledge of the severe phenotype of congenital BTK deficiency, otherwise known as X-linked agammaglobulinemia (XLA). The gene discussed is BTK; the disease is Bruton-type agammaglobulinemia.